Posted in Jobs, News
As reported by in the Montrose Review, a £1.46m R&D grant will not only help secure GlaxoSmithKline’s future at the Montrose site, but will create 25 jobs and safeguard 280.
The research and development grant has been made by the Scottish Enterprise and was announced by Scottish finance secretary John Swinney on Monday. It is hoped that the grant will support GSK’s innovation and help maintain Scotland’s position in the pharmaceutical’s industry. Speaking of the news, Swinney stated,
“The Scottish Government and our enterprise agencies are doing all we can to build sustainable economic growth for Scotland.
“This investment by GlaxoSmithKline in Montrose is looking towards the future and I’m encouraged that a world leading company is showing this commitment to the area.
“Scotland is globally renowned for innovation, enterprise and technology. The quality and skills of our workforce in life sciences have played an important part in the company’s decision, as has the research excellence of our institutions and the competitiveness of our business environment.
“The hard work by our partners at Scottish Enterprise and Scottish Development International also deserves praise. They have built-up an excellent understanding of this company and provided the most relevant support when required.”
Andy Ross, GlaxoSmithKline Montrose site director said: “We are very grateful to Scottish Enterprise for all their efforts in relation to the research and development grant.
“Their financial support will allow us to provide the right people, plant and expertise at a critical time for the GSK Montrose site as we look to introduce innovative new processes so as to maintain our global cost effectiveness.”
Posted in Industry News, News
As reported in This is Money.co.uk, the pharmaceutical company GlaxoSmithKline (GSK) is planning on building it’s first new UK factory in 30 years. This will create 1,000 jobs.
As Andrew Witty, CEO of GSK explains, the plan comes are a result of tax breaks on innovation introduced by Chancellor George Osbourne, ‘Because of changes in the UK tax regime, it will be our intention to bring more activity to Britain and take advantage of the situation here and increase our contribution to Britain. If it [corporation tax] is going to come down over the next few years, it will attract us to pay more tax here.’
The global pharma are considering Cumbria, County Durham and two locations in Scotland for their new factory. A decision is expected to be made in May.
Looking for a new position in the Pharmaceutical Industry? Click here to search our current pharmaceutical jobs now.
Posted in General, News
The international Pharmaceutical company, GlaxoSmithKline (GSK) have indicated that Barnard Castle in County Durham as one of the three possible locations for its first UK-based biopharmaceutical factory, potentially bringing hundreds of new science and pharmaceutical jobs to the area. The other possible sites for the factory are in Stevenage, in Hertfordshire, and Ulverston, in Cumbria.
A spokesman from the GSK plant in Barnard Castle said: “It is far too early to say when or where a biopharm plant would be built. GSK will consider a range of options as its pipeline of new biopharmaceutical products progresses and as implementation of the Patent Box scheme gets closer. The timing of the decision on where to build a biopharmaceutical plant is dependent upon the progress through GSK Research and Development of new biopharmaceutical products which is difficult to predict. It is certainly not likely to be taken in the short term.”
The new Biopharmaceutical factory has the potential to bring hundreds of new science and pharmaceutical jobs to the area. With an office in Durham and access to all the latest scientific vacancies in the area, CK Science is well placed to help you find the perfect science job for you. To contact our specialist scientific recruitment consultants based in Durham, please click here.
Posted in General, News
The world-class pharmaceutical company, GlaxoSmithKline (GSK), is set to spend £500 million on a new state-of-the-art biopharmaceutical manufacturing plant and on improving its facility in Ware, Hertfordshire. The move comes after a pre-Budget report reduced the rate of Corporation Tax on 10pc on income arising from UK patents.
It seems that over the past few months, GSK and the drug industry have been in talks with the government about the proposal, which has been labeled a “patent box”. Speaking of the ‘patent box’, Andrew Witty, chief executive of GSK, said: “The patent box is exactly the sort of active, long-term and creative support that we need from the Government to ensure that the UK remains an attractive place for highly skilled sectors such as pharmaceuticals. For GSK, assuming the new regime will apply to patents currently under development it will have the immediate impact of making the UK a priority area for future investments, particularly in manufacturing.”
There is much speculation regarding the location of the biopharma site, but Stevenage, Ulverston and Barnard Castle, where the company has existing sites, are all in the running. Products that could be developed there include Arzerra, for leukaemia, and Syncria, for type 2 diabetes.
This investment is GSK’s largest in the UK for at least a decade and highlights the impact that the new tax regime could have on companies investing in research and development. To read more about this story, please visit the Telegraph website.
CK Science is proud to assist world-class pharmaceutical companies such as GSK to recruit talented individuals. To search for your next science job, please click here.